Search

Your search keyword '"Mattoo, Aprajita"' showing total 17 results
Start Over Author "Mattoo, Aprajita"
17 results on '"Mattoo, Aprajita"'

1. Trials and Tribulations: Responses of ChatGPT to Patient Questions About Kidney Transplantation

Author

Xu, Jingzhi, Mankowski, Michal, Vanterpool, Karen B., Strauss, Alexandra T., Lonze, Bonnie E., Orandi, Babak J., Stewart, Darren, Bae, Sunjae, Ali, Nicole, Stern, Jeffrey, Mattoo, Aprajita, Robalino, Ryan, Soomro, Irfana, Weldon, Elaina, Oermann, Eric K., Aphinyanaphongs, Yin, Sidoti, Carolyn, McAdams-DeMarco, Mara, Massie, Allan B., Gentry, Sommer E., Segev, Dorry L., and Levan, Macey L.

Published
2024
Full Text
View/download PDF

4. Improving long-term kidney allograft survival by rethinking HLA compatibility: from molecular matching to non-HLA genes.

Author

Mattoo, Aprajita, Jaffe, Ian S., Keating, Brendan, Montgomery, Robert A., and Mangiola, Massimo

Subjects
KIDNEY exchange, HLA histocompatibility antigens, MOLECULAR biology, HISTOCOMPATIBILITY antigens, TRANSPLANTATION of organs, tissues, etc., DEAD, BRAIN death
Abstract

Optimizing immunologic compatibility in organ transplantation extends beyond the conventional approach of Human Leukocyte Antigen (HLA) antigen matching, which exhibits significant limitations. A broader comprehension of the roles of classical and non-classical HLA genes in transplantation is imperative for enhancing long-term graft survival. High-resolution molecular HLA genotyping, despite its inherent challenges, has emerged as the cornerstone for precise patient-donor compatibility assessment. Leveraging understanding of eplet biology and indirect immune activation, eplet mismatch calculators and the PIRCHE-II algorithm surpass traditional methods in predicting allograft rejection. Understanding minor histocompatibility antigens may also present an opportunity to personalize the compatibility process. While the application of molecular matching in deceased donor organ allocation presents multiple technical, logistical, and conceptual barriers, rendering it premature for mainstream use, several other areas of donor-recipient matching and posttransplant management are ready to incorporate molecular matching. Provision of molecular mismatch scores to physicians during potential organ offer evaluations could potentially amplify long-term outcomes. The implementation of molecular matching in living organ donation and kidney paired exchange programs is similarly viable. This article will explore the current understanding of immunologic matching in transplantation and the potential applications of epitope and non-epitope molecular biology and genetics in clinical transplantation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. The Renin-Angiotensin-Aldosterone Axis in a Living Human Recipient with Porcine Xenothymokidney and Intact Native Kidneys

Author

Eitan, Tal, Aljabban, Imad, Kim, Jacqueline, Jaffe, Ian, Khalil, Karen, Viscusi, Summer, Weldon, Elaina, Ayares, David, Kadosh, Bernard, Goldberg, Randal, Saraon, Tajinderpal, Reyentovich, Alex, Smith, Deane, Mehta, Sapna, Stern, Jeffrey, Griesemer, Adam, Montgomery, Robert, Moazami, Nader, Skolnik, Edward, Mattoo, Aprajita, and Tatapudi, Vasishta

Published
2025
Full Text
View/download PDF

8. Alpha-Gal-KO Xenothymokidney Response to Endogenous Arginine Vasopressin in a Living Human Recipient with a Durable Mechanical Circulatory Support Device

Author

Aljabban, Imad, Kim, Jacqueline, Jaffe, Ian, Khalil, Karen, Weldon, Elaina, Eitan, Tal, Viscusi, Summer, Kadosh, Bernard, Goldberg, Randal, Saraon, Tajinderpal, Reyentovich, Alex, Smith, Deane, Stern, Jeffrey, Griesemer, Adam, Montgomery, Robert, Moazami, Nader, Skolnik, Edward, Mattoo, Aprajita, and Tatapudi, Vasishta

Published
2025
Full Text
View/download PDF

9. Alpha-Gal-KO Xenothymokidney Function in a Living Human Recipient with a Durable Mechanical Circulatory Support Device

Author

Aljabban, Imad, Kim, Jacqueline, Mattoo, Aprajita, Tatapudi, Vasishta, Skolnik, Edward, Jaffe, Ian, Khalil, Karen, Weldon, Elaina, Eitan, Tal, Viscusi, Summer, Ayares, David, Kadosh, Bernard, Goldberg, Randal, Saraon, Tajinderpal, Reyentovich, Alex, Smith, Deane, Williams, Simon, Keating, Brendan, Mehta, Sapna, Mangiola, Massimo, Stern, Jeffrey, Griesemer, Adam, Moazami, Nader, and Montgomery, Robert

Published
2025
Full Text
View/download PDF

10. Real-time Intraoperative Quantification of Xenograft Blood Flow into a Porcine Xenothymokidney in a Living Human Recipient with a Left Ventricular Assist Device

Author

Kim, Jacqueline, Aljabban, Imad, Mattoo, Aprajita, Tatapudi, Vasishta, Skolnik, Edward, Jaffe, Ian, Khalil, Karen, Ratner, Molly, Viscusi, Summer, Weldon, Elaina, Ayares, David, Kadosh, Bernard, Goldberg, Randal, Saraon, Tajinderpal, Reyentovich, Alex, Smith, Deane, Griesemer, Adam, Montgomery, Robert, Moazami, Nader, and Stern, Jeffrey

Published
2025
Full Text
View/download PDF

13. A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*

Author

Lonze, Bonnie E., primary, Spiegler, Peter, additional, Wesson, Russell N., additional, Alachkar, Nada, additional, Petkova, Eva, additional, Weldon, Elaina P., additional, Dieter, Rebecca A., additional, Li, Yi, additional, Quinn, Max, additional, Mattoo, Aprajita, additional, Soomro, Irfana, additional, Cohen, Steven M., additional, Leung, Sherry, additional, Deterville, Cecilia L., additional, Landrum, B. Mark, additional, Ali, Muhammad Imran, additional, Cohen, David J., additional, Singer, Andrew L., additional, Sen, Ayan, additional, Chong, Edward, additional, Hochman, Judith S., additional, Troxel, Andrea B., additional, and Montgomery, Robert A., additional

Published
2022
Full Text
View/download PDF

17. Prophylactic 2-week Glecaprevir/Pibrentasvir in Hepatitis C positive to negative kidney transplantation.

Author

Dieter RA, Mattoo A, Hotchkis P, Jaffe IS, Weldon EP, Berger JC, Ali NM, Montgomery RA, and Lonze BE

Abstract

Background and Hypothesis: Hepatitis C virus (HCV) positive-to-negative kidney transplants (KT) require direct acting antiviral therapy, but the optimal timing and duration remain unclear. We hypothesized that 14-day prophylactic course of glecaprevir/pibrentasvir 300/120 mg (GLE/PIB) would be safe and effective at treating donor-derived HCV viremia., Methods: This was a prospective, single-center, single-arm, open-label pilot study. 20 adult HCV negative recipients of HCV nucleic acid amplification test positive deceased-donor kidneys (HCV positive-to-negative) received a 14-day course of GLE/PIB, with the first dose pre-transplant. HCV RNA viral loads (VL) were monitored on post-operative days (POD) 1, 3, 7, and 13. If VL was undetectable on POD 13, GLE/PIB was stopped, and if detectable, GLE/PIB was continued to complete an 8-week course. Surveillance monitoring continued after treatment to ensure sustained viral response (SVR). The primary outcome was efficacy of 14-day prophylactic GLE/PIB. Secondary outcomes included patient and allograft survival, the incidence, timing, and clearance of HCV viremia, and safety events., Results: 7/20 subjects (35%) never developed detectable HCV viremia. Only one subject had a detectable, but nonquantifiable, VL on POD 13 and completed an 8-week course. All subjects achieved SVR 12 weeks post-treatment with no relapses through 1-year follow-up. Mean time to undetectable HCV RNA VL was 10.5 (±4.7) days and mean peak VL was 371 (±715) copies/mL. 6-month and 1-year patient and allograft survival were 100% and 95%., Conclusion: A 14-day course of prophylactic GLE/PIB is safe and effective for HCV positive-to-negative KT and may prevent HCV transmission or significantly reduce the VL for those with detectable transmission allowing for rapid clearance within 2 weeks., (© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results